Commissariat a L'energie Atomique

Université´ D'aix-Marseille

Université Paris Descartes

Assistance Publique Des Hopitaux De Marseille

Hla-G Technologies

Inserm

Pascale Paul

Edgardo Delfino Carosella

Nathalie Rouas-Freiss

Jean Dausset

Marek Kirszenbaum

Philippe Moreau

Sophie Caillat Zucman

Géraldine Porcu

The invention concerns a method for selecting tumours expressing HLA-G, sensitive to an anticancer treatment, which inhibits or prevents the HLA-G activity of said tumours and the uses thereof. Said method enable to establish either the HLA-G, transcription profile of a solid tumour or the HLA-G expression profile of a solid tumour. The method for establishing the HLA-G transcription profile consists in: (i) drawing a tumoral sample; (ii) extracting the mRNA; (iii) reverse transcription (RT) of said RNA: (iv) successive or simultaneous amplification of the cDNA's obtained in (iii) in the presence of primers specific to each HLA-G isoform and analysing the resulting amplification products, by electrophoresis and/or specific hybridisation and (v) establishing said sample HLA-G transcription profile. The method for establishing the HLA-G expression profile consists in: (i) drawing a tumoral sample; (ii) optionally marking said sample cells; (iii) carrying out a lysis of the cells; (iv) contacting said cells which have been subjected to lysis with different antibodies directed against the class I HLA-G antigens, to form, optionally HLA-G isform/antibodies complexes; and (v) establishing said sample HLA-G expression profile by detecting the complexes formed in step (iv).

Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses

The invention concerns the use of a eukaryotic cell coding for at least an HLA-G isoform, to obtain an immunomodulating medicine for inhibiting the activity of killer cells, in particular NK cells and/or for inhibiting the primary allogenic response, in parthologies or situations in which the killer cells are activated or for preparing a medicine to raise the inhibiting function of the isoform(s) expressed by said cells with respect to killer cells, in particular NK cells, in pathologies where these killer cells are inhibited by the molecule of the major histocompatibility complex of I HLA-G classes. The invention also concerns eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications. The invention further concerns transgenic animals specifically expressing at least an HLA-G isoform.

Eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications

Growing community of inventors

Paris, France

Pascale Paul